Skip to main content
OpenTrials
Completed

NCT Number: NCT02073019

A Phase I Study Evaluating Safety, Tolerability, PK and PD of BL-8040 for Stem Cell Mobilization in Healthy Volunteers

The purpose of this study is to determine whether BL-8040 is safe, tolerable and effective in the mobilization of Hematopoietic Stem Cells (HSC) in healthy volunteers

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–45 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Primary location

Hadassah Clinical Research Center

Jerusalem, Israel

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy male subjects
  • BMI between 18 and 30 kg/m2 and Weight ≥ 60 Kg
  • Subjects must be either surgically sterilized (vasectomy), or if their partner is of childbearing potential, must use two methods of contraception, one of which must be a barrier method, from the first dose until 3 months after the last dose
  • Subject is able and willing to comply with the requirements of the protocol

Exclusion criteria

  • History of clinically significant disease
  • Any illness within the 4 weeks prior to the screening examination
  • Any history of alcohol and/or drug of abuse addiction and/or active / past (up to 2 years before screening) nicotine consumption
  • Clinically relevant deviation from normal in the physical examination and vital signs at screening or baseline
  • Clinically relevant laboratory abnormalities identified at screening or baseline
  • Positive tests at screening for HIV I & II, hepatitis B and/or hepatitis C in both parts or positive tests for Syphilis, HTLV I & II and Nucleic Acid Test (NAT) for HIV and HBV
  • Positive test for urine drugs of abuse or by anamnesis (Barbiturates, Benzodiazepines, Amphetamines, Opiates, Cocaine, Cannabinoids, Methadone, Phencyclidine, and Tricyclic Antidepressants) and/or positive alcohol blood test
  • Subjects who have lost or donated in excess of 400 mL of blood within 3 months prior to Day 1 of the study

Treatment and study plan

BL-8040

Drug

Placebo

Drug

Primary outcomes

  1. Number of subjects with Adverse Events

    Time frame: Up to 7 days after treatment comletion

Sponsors and collaborators

Lead sponsor

BioLineRx, Ltd.

Industry

Registry information

Official study title

A Phase I, Two Part Study Exploring the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effect of Ascending Doses of BL-8040 in Healthy Subjects.

Important dates

Study start
2014
Primary completion
2015
Study completion
2015
First posted
Feb 27, 2014
Registry last updated
Jul 31, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.